Zentalis Pharmaceuticals (ZNTL) Net Margin (2024)
Zentalis Pharmaceuticals' (ZNTL) quarterly Net Margin came in at 176.71% in Q4 2024, down 813.86% quarter-over-quarter from 24.75% in Q1 2024.
Zentalis Pharmaceuticals (ZNTL) Net Margin (2024) Analysis & Trends
Zentalis Pharmaceuticals' Net Margin history runs 1 years deep, the most recent figure standing at 176.71% for Q4 2024.
- On a quarterly basis, Net Margin changed N/A year-over-year to 176.71% in Q4 2024; TTM through Sep 2025 was 555.8%, a 11366.0% decrease from a year earlier, with the FY2024 full-year figure at 246.0%, changed N/A from the prior year.
- Net Margin retreated to 176.71% in Q4 2024 per ZNTL's latest filing, from 24.75% in the prior quarter.
- Across five years, Net Margin topped out at 24.75% in Q1 2024 and bottomed at 176.71% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Zentalis Pharmaceuticals | 312.67 Mn | 312.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -176.71% |
| Mar 31, 2024 | 24.75% |